530 reports of this reaction
2.1% of all EPOETIN ALFA reports
#10 most reported adverse reaction
NEPHROGENIC SYSTEMIC FIBROSIS is the #10 most commonly reported adverse reaction for EPOETIN ALFA, manufactured by Amgen, Inc. There are 530 FDA adverse event reports linking EPOETIN ALFA to NEPHROGENIC SYSTEMIC FIBROSIS. This represents approximately 2.1% of all 25,704 adverse event reports for this drug.
Patients taking EPOETIN ALFA who experience nephrogenic systemic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROGENIC SYSTEMIC FIBROSIS is a less commonly reported adverse event for EPOETIN ALFA, but still significant enough to appear in the safety profile.
In addition to nephrogenic systemic fibrosis, the following adverse reactions have been reported for EPOETIN ALFA:
NEPHROGENIC SYSTEMIC FIBROSIS has been reported as an adverse event in 530 FDA reports for EPOETIN ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROGENIC SYSTEMIC FIBROSIS accounts for approximately 2.1% of all adverse event reports for EPOETIN ALFA, making it a notable side effect.
If you experience nephrogenic systemic fibrosis while taking EPOETIN ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.